Institutional Investors Drive Significant Activity in Henry Schein Shares

Henry Schein shares are experiencing notable price movements as institutional investors substantially reposition their holdings. Trading opened at $70.60 amid heightened volatility, reflecting shifting sentiment among major market participants.

Key indicators reveal Henry Schein's current market standing:
* Market Capitalization: $8.31 billion
* P/E Ratio: 22.77, indicating moderate valuation levels
* 52-Week Range: $60.56 to $82.49
* Beta of 0.84: Demonstrating lower volatility than broader market indices

The stock currently trades between its 50-day moving average of $66.93 and 200-day moving average of $69.11, suggesting a consolidation phase as investors assess future direction.

Major Institutions Reshape Portfolios

Recent regulatory filings show divergent strategies among Henry Schein's largest shareholders. Artisan Partners increased its stake by 0.9% during the second quarter, bringing its total position to 6.46 million shares. Meanwhile, Swedbank AB executed a more substantial buildup, expanding its holdings by 30.9% to reach an $84.5 million position.

Should investors sell immediately? Or is it worth buying Henry Schein?

Not all institutional players share this optimism. The Police & Firemen's Retirement System of New Jersey reduced its exposure by 7.8%, divesting 3,546 shares during the same period. This contrasting activity highlights the mixed outlook among professional investors.

Analyst Perspectives and Corporate Developments

Market researchers maintain a consensus "Hold" recommendation with an average price target of $76.08. However, individual forecasts reveal significant divergence. While some analysts project just $70 per share, Evercore ISI recently raised its target from $83 to $90 while assigning an "Outperform" rating.

This upgraded assessment follows Henry Schein's better-than-expected third-quarter 2025 performance, where the company surpassed both earnings per share and revenue projections. Investor attention now turns to December 2nd, when CEO Stanley Bergman is scheduled to present at the Piper Sandler Healthcare Conference, potentially offering new strategic insights.